A total of 21 patients with severe Alpha-1, or genetic emphysema, who have been accessing the life-changing Respreeza therapy for the most part following their participation in a clinical trial here are to lose access at the end of this month. The therapy has been provided up until now as part of a compassionate-use programme by the drug company, CSL Behring. However, patients were this month informed at a meeting with clinicians from Beaumont Hospital, Dublin, that the company has advised that it will no longer provide access to the therapy free of charge from September 30.
The hugely upsetting and disappointing decision was communicated by the company to medical staff at Beaumont Hospital who have had ongoing responsibility for the treatment and care of the patients concerned.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
